HER2- VEGFA BsAbによって誘発されたVEGFAとHER2- 過剰発現するがん細胞の共ファゴシトーシスは,抗腫瘍反応を改善する
Yang Lu1, Songbo Qiu1, Zhen Fan1
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, United States of America.
JCI insight
|September 4, 2025
まとめ
HER2とVEGFAを標的にする二固有の抗体は,がん細胞と腫瘍を誘発する成長因子をマクロファージに吸収させることで,抗腫瘍活動を強化する. この新しいアプローチは,臨床前モデルの生存率を向上させ,転移を減少させます.
科学分野:
- 腫瘍学
- 免疫学
- バイオテクノロジー
背景:
- 腫瘍の微小環境には 血管内皮成長因子A (VEGFA) のような 溶性因子が含まれており がんの成長を促します
- 抗体依存性細胞ファゴサイトーシス (ADCP) は,マクロファージが抗体で覆われた標的を吸収する免疫メカニズムである.
- がん細胞と溶解因子を同時に標的にすると,抗腫瘍効果が向上する可能性があります.
研究 の 目的:
- がん細胞と腫瘍の微小環境要因を共同標的とする双特定抗体 (BsAbs) の開発と評価.
- 癌細胞と溶解性標的のADCPを含む新しい抗腫瘍メカニズムを調査する.
- HER2- VEGFA BsAbsの治療の可能性を臨床前がんモデルで評価する.
主な方法:
- scFv- IgG形式でヒトの表皮成長因子受容体-2 (HER2) とVEGFAを標的とした設計された双特異抗体 (BsAbs).
- 腫瘍関連マクロファージによるHER2過剰発現がん細胞とVEGFAの共ファゴシトーシスの評価
- 免疫不全と免疫能力のあるマウスのモデルで評価された抗転移活性と生存効果.
主要な成果:
- HER2- VEGFA BsAbsは,親の抗体とは異なり,マクロファージによってがん細胞とVEGFAの共ファゴシトーシスを誘発した.
- BsAbsは,単独または組み合わせた親抗体と比較して,優れている抗転移活性と生存効果を示しました.
- 治療効果はマクロファージのFcγ受容体に依存した.
結論:
- HER2とVEGFAを標的にする二固有の抗体は,ADCPによる抗腫瘍活性強化のための新しい戦略を提供します.
- このアプローチはがん細胞と 腫瘍原性溶性因子を 効果的に標的としています
- この結果は,転移性および再発性HER2過剰発現の固体腫瘍の治療のための臨床試験を支持する.
関連する概念動画
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


